Vaccines work by teaching the immune system to specifically recognize and fight a pathogen. A successful vaccine must present an appropriate antigen to the immune system in such a way that the body mounts the necessary immune response and that response is maintained over time. Rapidly emerging preclinical and clinical results indicate major advantages for the use of adenovirus vectors as antigen delivery vehicles because they elicit the potent, broad and long lasting immune responses characteristic of highly effective vaccines.
GenVec has capitalized on our expertise with our platform adenovector technology and accompanying 293-ORF6 cell line used to produce the needed adenovectors to form funded collaborations for the development of vaccine candidates. Current collaborations include the Vaccine Research Center/National Institute of Allergy and Infectious Diseases/National Institutes of Health for the development of RSV vaccine candidates, Naval Medical Research Center and Malaria Vaccine Initiative for the development of malaria vaccine candidates, and the United States Department of Agriculture/Agricultural Research Services and the Department of Homeland Security for the development of anti-virals and vaccines to treat foot and mouth disease in large hoofed animals.